inclusion criteria: male or female hospitalized patients ≥ 18 years (i.e., at least 18 years old at the time of randomization), having given their written consent. having a positive rt-pcr test for covid-19 presenting with symptoms of covid-19, including: cough or shortness of breath or difficulty breathing or at least 2 of the following fever, defined as any body temperature 38°c chills repeated shaking with chills muscle pain headache sore throat new loss of taste or smell presenting with signs of moderate but progressive pulmonary disease with: respiratory symptoms (cough, dyspnea, etc.), uni- or bilateral ground-glass opacities, or pulmonary infiltrates on chest radiograph and/or ct scan, clinical and biological evidence of progression over the past 48hrs. effective birth control that should have been in place for at least 2 months in non-menopausal women and 4 months for men after imp administration. birth control methods considered to be highly effective include: combined (estrogen-progestogen) hormonal contraception associated with the inhibition of ovulation: oral, intravaginal, transdermal, progesterone-only hormonal contraception associated with the inhibition of ovulation: oral, injectable, implantable, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner. women of child-bearing potential must have negative results of a urinary or plasma pregnancy test (serum hcg).

inclusion criteria: male or female hospitalized patients ≥ 18 years (i.e., at least 18 years old at the time of randomization), having given their written consent. having a positive rt-pcr test for covid-19 presenting with symptoms of covid-19, including: cough or shortness of breath or difficulty breathing or at least 2 of the following fever, defined as any body temperature 38°c chills repeated shaking with chills muscle pain headache sore throat new loss of taste or smell presenting with signs of moderate but progressive pulmonary disease with: respiratory symptoms (cough, dyspnea, etc.), uni- or bilateral ground-glass opacities, or pulmonary infiltrates on chest radiograph and/or ct scan, clinical and biological evidence of progression over the past 48hrs. effective birth control that should have been in place for at least 2 months in non-menopausal women and 4 months for men after imp administration. birth control methods considered to be highly effective include: combined (estrogen-progestogen) hormonal contraception associated with the inhibition of ovulation: oral, intravaginal, transdermal, progesterone-only hormonal contraception associated with the inhibition of ovulation: oral, injectable, implantable, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner. women of child-bearing potential must have negative results of a urinary or plasma pregnancy test (serum hcg).

inclusion criteria: 1. male or female hospitalized patients ≥ 18 years (i.e., at least 18 years old at the time of randomization), having given their written consent. 2. having a positive rt-pcr test for covid-19 3. presenting with symptoms of covid-19, including: - cough or - shortness of breath or difficulty breathing or at least 2 of the following - fever, defined as any body temperature 38°c - chills - repeated shaking with chills - muscle pain - headache - sore throat - new loss of taste or smell 4. presenting with signs of moderate but progressive pulmonary disease with: - respiratory symptoms (cough, dyspnea, etc.), - uni- or bilateral ground-glass opacities, or pulmonary infiltrates on chest radiograph and/or ct scan, - clinical and biological evidence of progression over the past 48hrs. 5. effective birth control that should have been in place for at least 2 months in non-menopausal women and 4 months for men after imp administration. birth control methods considered to be highly effective include: - combined (estrogen-progestogen) hormonal contraception associated with the inhibition of ovulation: oral, intravaginal, transdermal, - progesterone-only hormonal contraception associated with the inhibition of ovulation: oral, injectable, implantable, - intrauterine device, - intrauterine hormone-releasing system, - bilateral tubal occlusion, - vasectomized partner. 6. women of child-bearing potential must have negative results of a urinary or plasma pregnancy test (serum hcg).

inclusion criteria: 1. male or female hospitalized patients ≥ 18 years (i.e., at least 18 years old at the time of randomization), having given their written consent. 2. having a positive rt-pcr test for covid-19 3. presenting with symptoms of covid-19, including: - cough or - shortness of breath or difficulty breathing or at least 2 of the following - fever, defined as any body temperature 38°c - chills - repeated shaking with chills - muscle pain - headache - sore throat - new loss of taste or smell 4. presenting with signs of moderate but progressive pulmonary disease with: - respiratory symptoms (cough, dyspnea, etc.), - uni- or bilateral ground-glass opacities, or pulmonary infiltrates on chest radiograph and/or ct scan, - clinical and biological evidence of progression over the past 48hrs. 5. effective birth control that should have been in place for at least 2 months in non-menopausal women and 4 months for men after imp administration. birth control methods considered to be highly effective include: - combined (estrogen-progestogen) hormonal contraception associated with the inhibition of ovulation: oral, intravaginal, transdermal, - progesterone-only hormonal contraception associated with the inhibition of ovulation: oral, injectable, implantable, - intrauterine device, - intrauterine hormone-releasing system, - bilateral tubal occlusion, - vasectomized partner. 6. women of child-bearing potential must have negative results of a urinary or plasma pregnancy test (serum hcg).